GHK-Cu injection vs topical: what the studies show
Reviewed 26 sourcesPublished by PepVault
GHK-Cu's studies split by route: what serums, gels and microneedling measured in people, what injection measured in animals, and why FDA splits it too.

- Last reviewed
- Sources
- 26
- Questions
- 9
- Compounds
- 1
The short answer
Nearly all of GHK-Cu's human evidence is topical: a serum trial that cut wrinkle volume, a small eyebrow trial, and wound gels and creams that helped one kind of ulcer but not another. Injected on its own, GHK-Cu has never been tested in a person; the only human injection reports are mixtures. The injection data comes from rats, mice and dogs.
Evidence: In people, five small controlled topical trials and uncontrolled reports of mixtures given by microneedle or injection; no human trial of injected GHK-Cu alone. Injection and nasal-spray results are from rats, mice and dogs.

Which routes has GHK-Cu been studied by?
GHK-Cu is a copper peptide: three amino acids, glycine, histidine and lysine, holding one copper ion. People use it two main ways, as a serum or cream on the skin, or as a shot under the skin (subcutaneous, explained at pepvault.app/glossary/subcutaneous). Microneedling, which pokes tiny channels in the skin before a serum goes on, sits between the two. Sorted by route and by who was studied, the published work looks like this.
| Route | In people | In animals | In cells or skin outside the body |
|---|---|---|---|
| Serum, cream or gel on the skin | 5 controlled trials of GHK-Cu itself: wrinkles, laser recovery, two kinds of ulcer, eyebrows12345 | Wound models, outside this guide's count | Many: fibroblasts, skin penetration7 |
| Microneedling, then a serum | One 7-man series of a three-drug mix11; no trial of GHK-Cu alone10 | Pig skin safety only8 | Human skin penetration8 |
| Injection | Two uncontrolled reports of multi-ingredient scalp mixes1213; no trial of GHK-Cu alone | Rats, mice, dogs1415161718 | Not applicable |
| Nasal spray | None | Mice2021 | None |

Most of the human column is on the skin, and every controlled trial in it is topical. A 2026 systematic review that included 20 studies of GHK-Cu alone for aesthetic uses counted 18 preclinical studies and 2 randomized trials, the laser and wrinkle trials below, both topical24.

What has GHK-Cu on the skin done in people?
| Trial | What went on the skin | Who | What it found |
|---|---|---|---|
| Badenhorst 20161 | GHK-Cu serum in lipid nano-carriers, twice daily | 40 women aged 40 to 65, 8 weeks | Wrinkle volume fell more than with the plain serum or a Matrixyl 3000 product |
| Miller 20062 | Skin care with or without GHK-Cu after CO2 laser | 13 patients, 12 weeks | No difference on blinded scoring; patients rated their skin better (P = .04) |
| Mulder 19943 | GHK-Cu gel on diabetic foot ulcers | Multicentre, vehicle-controlled | Median closure 98.5% vs 60.8% |
| Bishop 19924 | 0.4% copper tripeptide cream on venous leg ulcers | 86 patients | No better than placebo |
| Bo 20265 | 2% GHK-Cu serum on one eyebrow, placebo on the other | 18 adults, 12 weeks | More and thicker brow hairs on the treated side |
One more scalp trial is often quoted as topical GHK. It used a spray of GHK bonded to another active, 5-aminolevulinic acid, with no copper, and raised hair counts but not thickness in 45 men6. What each of these trials means for wrinkles and hair is in our guide GHK-Cu for skin and hair (pepvault.app/guides/ghk-cu-skin-and-hair). This guide stays on the route.
Does GHK-Cu get through the skin?
Some does, and how much depends on the test. GHK-Cu dissolves in water, and the skin's outer layer is built to keep water-loving molecules out9. Two lab teams measured it on human skin taken from the body.

- Hostynek 2011: a 0.68% GHK-Cu solution sat on skin sliced to a set thickness for 48 hours. About 136 micrograms of copper per square centimetre crossed it, and about 97 more stayed held in the skin as a depot. The test measured copper, not the peptide7.
- Li 2015: in 9 hours, almost no peptide or copper crossed intact human skin. After the skin was pretreated with microneedles, 134 nanomoles of peptide and 705 nanomoles of copper crossed8.
Species note: both are human skin in a diffusion cell outside the body, not a person. They show how much can cross the barrier, not what it then does in a face.
Peptide SkySee GHK-Cu as a molecule53 peptides as a night sky in 3D. Each star opens into its molecule, one bead per amino acid, with the measured shape where one exists.Open the Peptide SkyWhat does microneedling add?
On the bench, a lot: Li's team went from almost nothing to a measurable flow of peptide, and saw no obvious skin irritation in their pig tests8. In people, it has barely been tried. A 2026 systematic review of GHK-Cu and microneedles says this route has yet to be evaluated in a single registered, adequately powered human randomized trial10.
The closest human report used a tattoo machine to push a solution of minoxidil, dutasteride and 1.2% copper peptides into the scalps of 7 men with pattern hair loss, five monthly sessions. The median share of bare scalp on top fell from 40% to 7.5% after 5 months, with no control group, and the copper peptide's share can't be separated from the two hair-loss drugs11.
What has injected GHK-Cu been measured to do?
In people, nothing on its own. The two human injection reports are both scalp mixtures. One gave 1,000 patients intradermal shots of six growth factors and peptides, copper tripeptide-1 among them, with no control group12. The other treated 18,918 men with oral finasteride, minoxidil and a monthly injected solution of 14 ingredients, copper tripeptide one of them, also with no control group13. A 2026 narrative review for orthopaedic surgeons found no clinical data supporting GHK-Cu for musculoskeletal conditions25. A ClinicalTrials.gov search on November 20, 2026 found no registered trial of injected GHK-Cu.
In animals there is real work. Half of it injects GHK-Cu into or near the tissue being studied; the rest went into the abdomen or a vein:
| Study | Animal | Where it was injected | What it found |
|---|---|---|---|
| Maquart 199314 | Rats | Into wound chambers under the skin | More collagen and glycosaminoglycans as the amount rose |
| Swaim 199615 | 12 dogs | A tripeptide-copper complex (the abstract does not name it GHK-Cu) into paw-pad wounds | Most type I collagen of the three groups at day 14 |
| Fu 201516 | 72 rats | Into the knee after ACL surgery | Less knee laxity at 6 weeks, no difference at 12 |
| Ma 202017 | Mice | Into the abdomen (intraperitoneal) | Less lung inflammation and scarring after bleomycin |
| Zhang 202218 | Mice | Into the abdomen | Less emphysema after 12 weeks of cigarette smoke |
| Endo 199719 | Rats | GHK into a vein, once (the abstract names no copper) | GHK broken down quickly to a two-amino-acid fragment |
Species note: every result in this table is from rats, mice or dogs. None measured skin or hair after a shot under the skin, which is how people inject it, and no study we found has measured its half-life in people.
What about nasal sprays and other routes?
A University of Washington group gives GHK-Cu as a nasal spray (intranasal, see pepvault.app/glossary/intranasal) to mice. In mice bred to develop Alzheimer's-like disease, three months of it delayed cognitive decline and reduced amyloid plaques20. Their 2026 preprint, not yet peer reviewed, compared routes in aged mice: 8 weeks of nasal spray improved a learning task in both sexes, while 5 days of abdominal injection gave a short-lived gain in males only, and the two routes switched on different gene programs in the brain21. The two arms also differed in length, 8 weeks against 5 days, so the study cannot say whether the route or the time on treatment made the difference.
Patches are the other route people ask about. The one registered human study we found is a device study of a commercial patch, LifeWave's X39: it measures whether a week of wearing it raises blood GHK and GHK-Cu against a placebo patch, and the record does not say the patch contains GHK-Cu. On November 20, 2026 it had not started recruiting; its planned start is January 202726.

Why does FDA treat the routes differently?
Because the route was the dividing line in the nominations. On FDA's list of substances nominated for compounding (updated May 14, 2026), "GHK-Cu (except for injectable routes of administration)" is back in category 1, under evaluation, after a nominator said it meant to withdraw only the injectable route. FDA plans to consult its compounding advisory committee before the end of February 202722.
The injectable form sits on FDA's page of substances that may present significant safety risks, among those nominated and withdrawn. FDA writes that compounded injectable GHK-Cu "may pose risk for immunogenicity" (an immune reaction to the drug) from aggregation and impurities, and that "there are limited data in humans to inform safety-related considerations"23. That is a statement about missing data, not a reported harm. The full status is at pepvault.app/peptides/ghk-cu/legal-status.
Which route has data for which goal?
| Goal | Route with human data | What that data is |
|---|---|---|
| Facial wrinkles | Serum on the skin | One 40-woman randomized trial, positive1 |
| Healing after laser | Skin care on the skin | One 13-patient trial, no measured difference2 |
| Chronic wounds | Gel or cream on the wound | Positive on diabetic foot ulcers, negative on venous ulcers34 |
| Brows or scalp hair | Serum on the skin; mixes by microneedle or injection | One 18-person eyebrow trial5; uncontrolled scalp mixes111213 |
| Anything inside the body (lungs, joints, brain) | None | Rats and mice only1617182021 |
Injection's case rests on bypassing the skin barrier and reaching the blood, not on a human result: no trial has compared the two routes, and none has tested a shot of GHK-Cu alone for skin or hair.
Commonly reported: in the posts of 46 people we read (pepvault.app/peptides/ghk-cu/reviews, checked November 19, 2026), smoother skin was the effect mentioned most, and the sting of the injection the most-mentioned downside. Many injected it; some put it on the skin or under the tongue. The solution is blue, the colour of its copper.
If you inject, the PepVault app records where each shot went so you can rotate sites, and reminds you at the dose time you set. Log it in PepVault
When to get help Redness and a sting that pass on their own are the usual report; a site that keeps getting hotter, more swollen or more painful is worth showing to a doctor.
Where to read more
- The library page, pepvault.app/peptides/ghk-cu, with its side effects, how long to work and legal status pages.
- Study pages for the trials and animal work, such as pepvault.app/research/ghk-cu-mulder-1994, /research/ghk-cu-miller-2006 and /research/ghk-cu-maquart-1993.
- Terms used here: pepvault.app/glossary/in-vitro, /glossary/in-vivo, /glossary/bioavailability, /glossary/open-label and /glossary/immunogenicity.
Sources
- Badenhorst T, Svirskis D, Merrilees M et al. Effects of GHK-Cu on MMP and TIMP expression, collagen and elastin production, and facial wrinkle parameters. J Aging Sci. 2016;4:166. doi.org
- Miller TR et al. Effects of topical copper tripeptide complex on CO2 laser-resurfaced skin. Arch Facial Plast Surg. 2006. PubMed 16847171
- Mulder GD et al. Enhanced healing of ulcers in patients with diabetes by topical treatment with glycyl-l-histidyl-l-lysine copper. Wound Repair Regen. 1994. PubMed 17147644
- Bishop JB et al. A prospective randomized evaluator-blinded trial of two potential wound healing agents for the treatment of venous stasis ulcers. J Vasc Surg. 1992. PubMed 1495150
- Bo SL, Nararatwanchai T, Supornpun N, Poomarapan K, Thaploka S. The efficacy of 2% copper peptide (GHK-Cu) serum for eyebrow hypotrichosis: a randomized, double-blind, vehicle-controlled, split-face comparative study. Procedia of Multidisciplinary Research. 2026;4(5):16. so09.tci-thaijo.org
- Lee WJ et al. Efficacy of a complex of 5-aminolevulinic acid and glycyl-histidyl-lysine peptide on hair growth. Ann Dermatol. 2016. PubMed 27489425
- Hostynek JJ, Dreher F, Maibach HI. Human skin penetration of a copper tripeptide in vitro as a function of skin layer. Inflamm Res. 2011. PubMed 20721598
- Li H et al. Microneedle-mediated delivery of copper peptide through skin. Pharm Res. 2015. PubMed 25690343
- Mortazavi SM, Moghimi HR. Skin permeability, a dismissed necessity for anti-wrinkle peptide performance. Int J Cosmet Sci. 2022. PubMed 35302659
- Najafi N et al. A systematic review of the mechanisms and therapeutic applications of GHK-Cu in topical microneedle delivery: a case for expanded clinical trials. Arch Intern Med Res. 2026. PubMed 42787770
- Kuceki G et al. Enhanced hair regrowth with five monthly sessions of minoxidil-dutasteride-copper peptides tattooing for androgenetic alopecia assessed by artificial intelligence and blinded evaluators. JAAD Int. 2025. PubMed 40225275
- Kapoor R, Shome D. Intradermal injections of a hair growth factor formulation for enhancement of human hair regrowth: safety and efficacy evaluation in a first-in-man pilot clinical study. J Cosmet Laser Ther. 2018. PubMed 29482481
- Tanaka Y et al. Androgenetic alopecia treatment in Asian men. J Clin Aesthet Dermatol. 2018. PubMed 30057663
- Maquart FX et al. In vivo stimulation of connective tissue accumulation by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+ in rat experimental wounds. J Clin Invest. 1993. PubMed 8227353
- Swaim SF et al. Effect of locally injected medications on healing of pad wounds in dogs. Am J Vet Res. 1996. PubMed 8669775
- Fu SC et al. Tripeptide-copper complex GHK-Cu (II) transiently improved healing outcome in a rat model of ACL reconstruction. J Orthop Res. 2015. PubMed 25731775
- Ma WH et al. Protective effects of GHK-Cu in bleomycin-induced pulmonary fibrosis via anti-oxidative stress and anti-inflammation pathways. Life Sci. 2020. PubMed 31809714
- Zhang Q et al. Glycyl-L-histidyl-L-lysine-Cu(2+) attenuates cigarette smoke-induced pulmonary emphysema and inflammation by reducing oxidative stress pathway. Front Mol Biosci. 2022. PubMed 35936787
- Endo T, Miyagi M, Ujiie A. Simultaneous determination of glycyl-L-histidyl-L-lysine and its metabolite, L-histidyl-L-lysine, in rat plasma by HPLC with post-column derivatization. J Chromatogr B. 1997. PubMed 9187381
- Tucker M et al. Behavioral and neuropathological features of Alzheimer's disease are attenuated in 5xFAD mice treated with intranasal GHK peptide. Aging Pathobiol Ther. 2024. PubMed 40766919
- Mazzola J et al. Middle-aged mice treated with GHK-Cu peptide administered intraperitoneally or intranasally show behavioral rescue but divergent hippocampal aging programs. Res Sq (preprint). 2026. PubMed 42245779
- U.S. Food and Drug Administration. Bulk drug substances nominated for use in compounding under section 503A of the Federal Food, Drug, and Cosmetic Act (updated May 14, 2026). fda.gov
- U.S. Food and Drug Administration. Certain bulk drug substances for use in compounding that may present significant safety risks (content current as of April 22, 2026). fda.gov
- Mokhtar J et al. The regenerative potential of GHK-Cu in aesthetic medicine. Aesthet Surg J. 2026. PubMed 42619529
- Mayfield CK et al. Injectable peptide therapy: a primer for orthopaedic and sports medicine physicians. Am J Sports Med. 2026. PubMed 41476424
- ClinicalTrials.gov. NCT07706361: Two-part study of the effects of the X39 patch on circulating GHK and GHK-Cu levels in healthy adults (LifeWave, Inc.; not yet recruiting; checked November 20, 2026). clinicaltrials.gov
Newsletter · Weekly
The weekly peptide briefing.
New guides, the week’s peptide news, one tool. Free, one email a week, unsubscribe anytime.